Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06388889 · ClinicalTrials.gov registry record · Phase 3
Phase III Long-Term Extension Study With Dexpramipexole
A Phase 3 study, sponsored by Areteia Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 509
- Enrollment target
NCT06388889 is a Phase 3 study that was terminated before completion, run by Areteia Therapeutics. The registered enrollment target is 509 participants.
The verdict
NCT06388889, a Phase 3 study, was terminated before completion, sponsored by Areteia Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 509 participants
- Enrollment target
Study Summary
The goal of this clinical trial\] is to evaluate the long term safety of dexpramipexole treatment in participants with severe asthma, aged ≥18 years, on Global Initiative for Asthma (GINA) 2021 \[GINA, 2021\] Step 4 or 5 therapy and who completed either of the Phase III studies EXHALE-2 or EXHALE-3.
Interventions
- DRUG Dexpramipexole Dihydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 509 participants |
| Start Date | 2024-06-12 |
| Est. Completion | 2025-12-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06388889
The ClinicalTrials.gov registry entry for NCT06388889 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 509 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Areteia Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dexpramipexole Dihydrochloride is the first listed.
NCT06388889 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06388889 about?
NCT06388889 is a clinical study titled "Phase III Long-Term Extension Study With Dexpramipexole". The goal of this clinical trial\] is to evaluate the long term safety of dexpramipexole treatment in participants with severe asthma, aged ≥18 years, on Global Initiative for Asthma (GINA) 2021 \[GINA, 2021\] Step 4 or 5 therapy and who completed either of the Phase III studies EXHALE-2 or EXHALE-3.
What is the current status of trial NCT06388889?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 509 participants. The study started on 2024-06-12. Estimated completion is 2025-12-08.
What interventions are being tested in trial NCT06388889?
The interventions under investigation include: Dexpramipexole Dihydrochloride (DRUG).
Who is sponsoring clinical trial NCT06388889?
This trial is sponsored by Areteia Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.